Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | BLVRB | P30043 | 1/20 | 0.52 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3709865 | 0.90 | XDH (0.63) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL1986815 | 0.87 | XDH (0.77) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL12373477 | 0.85 | XDH (0.80) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL12598890 | 0.84 | XDH (0.53) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL12373472 | 0.84 | XDH (1.00) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL12373475 | 0.83 | XDH (1.00) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL3706339 | 0.80 | XDH (0.82) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL12316980 | 0.78 | XDH (0.61) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL3709822 | 0.78 | XDH (0.54) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL1988257 | 0.78 | XDH (0.71) | XDHABCC4ABCB11PGRCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, PON1, CBR1 | XDH 1/4885ABCC4 398/4885ABCB11 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.